Validating cancer drug targets

A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as ‘validated’ before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.

[1]  James F Amatruda,et al.  Zebrafish as a cancer model system. , 2002, Cancer cell.

[2]  G. Jenster,et al.  The role of the androgen receptor in the development and progression of prostate cancer. , 1999, Seminars in oncology.

[3]  G. Hannon,et al.  RNA-interference-based functional genomics in mammalian cells: reverse genetics coming of age , 2004, Oncogene.

[4]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Mills,et al.  Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[7]  H. Horvitz,et al.  C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2 , 1994, Cell.

[8]  J. Lyons,et al.  Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. , 2005, Current opinion in pharmacology.

[9]  B. Pasche,et al.  Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. , 2004, Critical reviews in oncology/hematology.

[10]  Hao Jiang,et al.  Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[12]  H. Koeffler,et al.  Comparative Analysis of Genes Regulated by PML/RARα and PLZF/RARα in Response to Retinoic Acid Using Oligonucleotide Arrays , 2003 .

[13]  K. Korach,et al.  Tamoxifen versus aromatase inhibitors for breast cancer prevention. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Michael Koutsilieris,et al.  The Akt pathway: molecular targets for anti-cancer drug development. , 2004, Current cancer drug targets.

[15]  K. Kinzler,et al.  Use of isogenic human cancer cells for high-throughput screening and drug discovery , 2001, Nature Biotechnology.

[16]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[17]  F. Mascarelli,et al.  Roles of Stem Cell Factor/c-Kit and Effects of Glivec®/STI571 in Human Uveal Melanoma Cell Tumorigenesis* , 2004, Journal of Biological Chemistry.

[18]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[19]  Alexander Kamb,et al.  What's wrong with our cancer models? , 2005, Nature Reviews Drug Discovery.

[20]  M. Beeram,et al.  Raf: a strategic target for therapeutic development against cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Sausville,et al.  Target Selection Issues in Drug Discovery and Development , 2004, Journal of chemotherapy.

[22]  P. Jänne,et al.  Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[24]  N. Hayward,et al.  Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. , 1996, The American journal of pathology.

[25]  D. Hockenbery,et al.  Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. , 2004, Biochimica et biophysica acta.

[26]  C. Kang,et al.  An in vitro Study on the Suppressive Effect of Glioma Cell Growth Induced by Plasmid-Based Small Interference RNA (siRNA) Targeting Human Epidermal Growth Factor Receptor , 2005, Journal of Neuro-Oncology.

[27]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[28]  H. Richardson,et al.  Using Drosophila melanogaster to map human cancer pathways , 2005, Nature Reviews Cancer.

[29]  J. Tao,et al.  Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach , 2005, The British journal of dermatology.

[30]  Michael Ittmann,et al.  Mutation of the androgen receptor causes oncogenic transformation of the prostate. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[32]  C. Mermel,et al.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Dick,et al.  Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells , 2003, Nature Medicine.

[34]  W. Muller,et al.  The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. , 1999, Experimental cell research.

[35]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[36]  S. Kitareewan,et al.  Retinoid target genes in acute promyelocytic leukemia , 2003, Leukemia.

[37]  L. Hartwell,et al.  Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.

[38]  Min Lu,et al.  Expression of estrogen receptor α, retinoic acid receptor α and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells , 2005, Oncogene.

[39]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[40]  J. Marx.  Encouraging Results for Second-Generation Antiangiogenesis Drugs , 2005, Science.

[41]  Tianyu Li,et al.  Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. , 2005, Journal of the National Cancer Institute.

[42]  R. Tekmal,et al.  Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation. , 2005, Cancer research.

[43]  C. Lengauer,et al.  Cancer drug discovery through collaboration , 2005, Nature Reviews Drug Discovery.

[44]  E. Dmitrovsky,et al.  Transgenic expression of PML/RARalpha impairs myelopoiesis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  K. Kinzler,et al.  Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. , 2004, Nucleic acids research.

[46]  B. V. Rao,et al.  Measurement of a linear free energy relationship one molecule at a time , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Simon,et al.  Yeast as a model system for anticancer drug discovery , 2004, Nature Reviews Cancer.

[48]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[49]  P. Jolicoeur,et al.  Fine allelotyping of Erbb2‐induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor‐suppressor loci , 2006, Genes, chromosomes & cancer.

[50]  N. Heisterkamp,et al.  Early events in leukemogenesis in P190Bcr-abl transgenic mice , 2000, Oncogene.

[51]  M. Olson,et al.  Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. , 2005, Current opinion in genetics & development.

[52]  R. Weinberg,et al.  Isolation of a transforming sequence from a human bladder carcinoma cell line , 1982, Cell.

[53]  Y. Matsuzawa,et al.  Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. , 1996, Blood.

[54]  B. Druker,et al.  Oncogenes and Tumor Suppressors (795 articles) , 2004 .

[55]  L. Emens.  Trastuzumab: Targeted Therapy for the Management of HER-2/neu-Overexpressing Metastatic Breast Cancer , 2005, American journal of therapeutics.

[56]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[57]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[58]  V. Jordan,et al.  The estrogen receptor: a model for molecular medicine. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.